Today on Drug Discovery & Development
How Accenture and AWS are upgrading Merck’s IT and drug discovery R&D engine
Historically, the pharma sector has exhibited a degree of caution in adopting emerging technologies such as cloud computing and AI, given the sector’s stringent regulatory requirements, data security concerns, and the complexities involved in integrating new systems into legacy processes. The situation is beginning to shift considerably with the COVID-19 pandemic, in particular, acting as…Eversana’s AWS alliance aims to cut red tape in pharma regulatory paperwork
In July, the life sciences services company Eversana revealed it was partnering with AWS to tap generative AI (gen AI) for pharma and other life science customers. It aimed to “pharmatize” gen AI, as the company put it then. Now, the company has revealed the first technology from that partnership – a regulatory review automation…Drug Discovery and Development See More >
Genmab’s data-driven strategies speed up drug commercialization
Genmab’s senior vice president, global head of data science and AI, Hisham Hamadeh, describes the company’s journey to becoming “a data-driven decision-making company.” In one sense, there is little choice but to do so. “We’re swimming in data like never before. We’ve seen the volumes of data, the ability to compute on that data, and…
How Accenture and AWS are upgrading Merck’s IT and drug discovery R&D engine
Eversana’s AWS alliance aims to cut red tape in pharma regulatory paperwork
Biotech boomtowns: Comparing salaries and cost of living in 9 global hotspots
Organon reinforces commitment to women’s health beyond reproductive health
Sponsored Content See More >
Innovations in Baculovirus–Insect Cell Expression SystemsThe baculovirus–insect cell expression system—insect cells used in conjunction with the baculovirus expression vector system (BEVS)—remains a crucial technology for…
Patient Training is Broken – And Everyone is Paying For ItNoble International is working with Pharma and Specialty Pharmacy to fix the problem. The report, “The Current Paradigm for Biologic…
Noble Leads with its User-Centered Design StrategyBy Tim McLeroy, Executive Director of Marketing and Patient Services, Noble International At Noble, the patient journey drives everything we…
Using Real-World Data to Address COVID-19By Cheryl Reifsnyder, PhD As a leading provider of data and advanced analytics, Veradigm understands the critical role real-world data…
Discovering Antigen-specific Monoclonal Antibodies using Single B Cell ScreeningIntroduction Since the approval of Orthoclone OKT3 in 1986, more than 100 monoclonal antibodies (mAbs) have been approved by the…
A new way to access scientific papers?Losing university access doesn’t mean losing access to articles anymore By DeepDyve Digital Library Team Many researchers are surprised to…
These are not fireworks: The objective truthBy Jan Barghaan, Strategic Marketing Manager Life Science, Olympus Europa No, not fireworks — it’s actually a single colony of…
AI technology automates tedious cell culture work and analysesBy Joanna Hawryluk, PhD, Product Manager, Olympus Life Science Since the early 20th century, cell culture has been considered the…
What is Human AB serum?By Trevor Smith, MS MBA, Product Manager, Immune Cells Human AB Serum is a staple in the biological research field,…
Resolving binding kinetics on a microplate readerWith a better understanding of the causes and mechanisms behind diseases arises a need for new treatment options and drugs…
Noble expands its services for its clients into Human FactorsHuman Factors + (HF+) is a natural extension of Noble’s deep understanding of the patient experience relative to self-administering drug…
Micro 3D Printing Advances Biomarker DetectionResearchers in China have used Projection Micro Stereolithography (PµSL) to improve the fabrication of micropillar array electrodes (µAEs) for the…
Genomics/Proteomics See More >
Nvidia-Genentech AI drug discovery alliance unites computing brawn with biological brains
Technically, graphics processing and AI hardware powerhouse Nvidia is also a drug discovery company. It may not discover drugs in-house, but it has developed BioNeMo, a comprehensive generative AI platform for drug discovery and Clara, a collection of healthcare frameworks, applications, and tools, including for biopharma. Nvidia partners include Amgen, AstraZeneca, GSK and Insilico Medicine.…
Infectious Disease See More >
Vaccine mega-trials: Rare behemoths in the vaccine trial landscape
Abstract The vast majority of vaccines are prophylactic in nature. As a result, the demonstration of their efficacy paradoxically requires the infectious disease to occur among non-diseased study participants randomized between investigational vaccine and appropriate control groups. The statistics of vaccine efficacy (VE) calculation are nearly entirely and solely based on the number of observed…
Biden names 31 tech hubs: Here are 10 relevant to pharma and biotech
An overview of the RSV vaccine landscape: GSK aims to extend its approval of Arexvy?
Pfizer Ignite: Kathy Fernando’s vision for accelerating biotech innovation
The best-selling pharmaceuticals of 2023: Immunology and oncology return to prominence
Oncology See More >
How Lantern Pharma and Code Ocean partnered on oncology drug development
A vision for data-driven drug development in oncology When Peter Carr, principal software architect of Lantern Pharma, stepped into his full-time role in September 2020, the company was on the cusp of a transformation. While AI had been a focus for a number of years, a fresh infusion of cash provided a possibility of expanding…
A glimpse at Big Pharma’s upper echelon in the first three quarters of 2023
Insilico Medicine taps AI to nominate small molecule inhibitor ISM9274 as a preclinical cancer therapy
Click chemistry breakthroughs drive Shasqi and J&J cancer alliance